Trials / NCT06212297
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
Underway, not enrolling Phase 1 / Phase 2 Gene therapy
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
- Treatment
- LX101
- Gene
- RPE65
- Conditions
- Inherited Retinal Dystrophy
- Ages
- 6 Years to no upper limit
- Enrollment
- 9 participants
- Started
- 2023-09-12
- Main results expected
- 2025-02-06
- Results posted
- Not yet
- Record last updated
- 2025-06-29
What the study is testing
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.
Where it runs
China (1)
- Shanghai General Hospital, Shanghai, Shanghai Municipality